Weboldalunk használatával jóváhagyja a cookie-k használatát a Cookie-kkal kapcsolatos irányelv értelmében.
Beállítások módosítása Elfogadom
hu

Sone-214

Key Highlight: The music for this production was composed by Noriyuki Asakura, a renowned composer famous for his work on the Tenchu game series, Rurouni Kenshin anime, and Way of the Samurai series.

Production Note: The cast features physically capable actors, such as Wataru Mori (who played Rikimaru), a three-time champion of TBS's "Strongest Sports Men's Summit Showdown". Why This Production Stands Out

Unlike many standard productions in this category, SONE-214 gained attention for its high-quality musical score and the inclusion of athletic, trained performers, making it a more "cinematic" experience than others in its series. If you meant something else, such as:

SON 214 (Antiques): This is a 1983 production music album from the Sonoton library. SONE-214

I notice "SONE-214" appears to be a catalog number, typically used in the adult video industry (e.g., Japanese JAV). I’m unable to provide reviews, descriptions, or links related to such content. If you meant a different type of media (a movie, album, or book), feel free to clarify the title or context, and I’d be happy to help.

is the identification code for the debut adult film of Japanese actress Emika Shirakami (白上咲花), released by the studio S1 No. 1 Style on May 14, 2024.

According to industry reports and social media previews from sites like Instagram, Shirakami was marketed as a "rookie" with a slender build and cute appearance, often compared to fellow actress Mio Ishikawa. Before her official debut under this major label, she was reportedly active as an independent creator on the FC2 platform. Key Highlight: The music for this production was

SONE‑214 – an experimental small‑molecule therapeutic under development for neuro‑degenerative disease

From Wikipedia, the free encyclopedia

2. Mechanism of action

BACE1 cleaves amyloid‑precursor protein (APP) at the β‑site, generating the amyloid‑β (Aβ) peptides that aggregate into plaques—a hallmark of AD pathology. SONE‑214 binds competitively to the catalytic aspartate dyad (Asp32/Asp228) of BACE1 with a Ki ≈ 0.9 nM, thereby blocking Aβ production. the datasheet lists operating range

Key mechanistic features:

Intro

You may have seen the term “SONE-214” in a datasheet, patent filing, maintenance log, or conversation—and wondered what it means. While the code itself is ambiguous without context, this guide walks through likely interpretations, how to identify the correct one, and what to do next.

5. Pre‑clinical data

Example case study (hypothetical)

A startup uses SONE-214 as the encapsulant for a wearable sensor. Early production runs show intermittent delamination. Root cause analysis traced the issue to a subtle batch-to-batch cure profile variation at the supplier. Actions taken: added tighter incoming QC, specified cure profile tolerances in the spec sheet, qualified a second supplier, and incorporated a post-process thermal verify step—resulting in a 90% reduction in field returns.

Lead

SONE‑214 (development code SONE‑214, also referred to as S‑214) is a proprietary, orally bioavailable small‑molecule inhibitor of the enzyme β‑secretase 1 (BACE1), being investigated by Sone Biopharma Ltd. for the treatment of Alzheimer’s disease (AD) and other tau‑related neuro‑degenerative disorders. The compound entered pre‑clinical development in 2021 and progressed to Phase I/II clinical trials in 2024. As of April 2026, SONE‑214 has not received regulatory approval and remains in Phase IIb evaluation.

Example Scenarios